Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor

References

• SiegelRL, MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• ZhangL, BaiL, LiuX, et al. Factors related to rapid progression of non-small cell lung cancer in Chinese patients treated using single-agent immune checkpoint inhibitor treatment. Thorac Cancer. 2020;11(5):1170–1179. doi:10.1111/1759-7714.1337032134200
   PubMed Web of Science ®Google Scholar
• HuY, YangX, NieL, ZhaoD, AnJ, LiB. [Analysis of clinical characteristics and driver genes in 405 patients with lung cancer complicated with tuberculosis]. Zhongguo Fei Ai Za Zhi. 2020;23(5):337–342. Chinese. doi:10.3779/j.issn.1009-3419.2020.101.2532336065
   PubMedGoogle Scholar
• YuYH, LiaoCC, HsuWH, et al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol. 2011;6(1):32–37. doi:10.1097/JTO.0b013e3181fb4fcc21150470
   PubMed Web of Science ®Google Scholar
• NalbandianA, YanBS, PichuginA, BronsonRT, KramnikI. Lung carcinogenesis induced by chronic tuberculosis infection: the experimental model and genetic control. Oncogene. 2009;28(17):1928–1938. doi:10.1038/onc.2009.3219330024
   PubMed Web of Science ®Google Scholar
• FuW, SunH, ZhaoY, et al. BCAP31 drives TNBC development by modulating ligand-independent EGFR trafficking and spontaneous EGFR phosphorylation. Theranostics. 2019;9(22):6468–6484. doi:10.7150/thno.3538331588230
   PubMed Web of Science ®Google Scholar
• HwangIK, PaikSS, LeeSH. Impact of pulmonary tuberculosis on the EGFR mutational status and clinical outcome in patients with lung adenocarcinoma. Cancer Res Treat. 2019;51(1):158–168. doi:10.4143/crt.2018.08429621876
   PubMed Web of Science ®Google Scholar
• YuHA, ArcilaME, HellmannMD, KrisMG, LadanyiM, RielyGJ. Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing. Ann Oncol. 2014;25(2):423–428. doi:10.1093/annonc/mdt57324478319
   PubMed Web of Science ®Google Scholar
• MuW, JiangL, ZhangJ, et al. Non-invasive decision support for NSCLC treatment using PET/CT radiomics. Nat Commun. 2020;11(1):5228. doi:10.1038/s41467-020-19116-x33067442
   PubMed Web of Science ®Google Scholar
• WoodruffPG, WolffM, HohlfeldJM, et al. Safety and efficacy of an inhaled epidermal growth factor receptor inhibitor (BIBW 2948 BS) in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(5):438–445. doi:10.1164/rccm.200909-1415OC20007923
   PubMed Web of Science ®Google Scholar
• VallathS, HyndsRE, SucconyL, JanesSM, GiangrecoA. Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities. Eur Respir J. 2014;44(2):513–522. doi:10.1183/09031936.0014641324435005
   PubMed Web of Science ®Google Scholar
• LuoYH, WuCH, WuWS, et al. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs. J Thorac Oncol. 2012;7(2):299–305. doi:10.1097/JTO.0b013e31823c588d22173705
   PubMed Web of Science ®Google Scholar
• SwaislandHC, RansonM, SmithRP, et al. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. 2005;44(10):1067–1081. doi:10.2165/00003088-200544100-0000516176119
   PubMed Web of Science ®Google Scholar
• DickinsonPA, CantariniMV, CollierJ, et al. Metabolic disposition of osimertinib in rats, dogs, and humans: insights into a drug designed to bind covalently to a cysteine residue of epidermal growth factor receptor. Drug Metab Dispos. 2016;44(8):1201–1212. doi:10.1124/dmd.115.06920327226351
   PubMed Web of Science ®Google Scholar
• VishwanathanK, DickinsonPA, SoK, et al. The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib. Br J Clin Pharmacol. 2018;84(6):1156–1169. doi:10.1111/bcp.1353429381826
   PubMed Web of Science ®Google Scholar
• ChangCH, LeeCH, HoCC, WangJY, YuCJ. Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis. Medicine. 2015;94(4):e444. doi:10.1097/MD.000000000000044425634180
   PubMed Web of Science ®Google Scholar
• ChristopoulosA, SaifMW, SarrisEG, SyrigosKN. Epidemiology of active tuberculosis in lung cancer patients: a systematic review. Clin Respir J. 2014;8(4):375–381. doi:10.1111/crj.1209424345074
   PubMed Web of Science ®Google Scholar
• SilvaDR, ValentiniDFJr, MullerAM, de AlmeidaCP, Dalcin PdeT. Pulmonary tuberculosis and lung cancer: simultaneous and sequential occurrence. J Bras Pneumol. 2013;39(4):484–489. doi:10.1590/S1806-3713201300040001324068271
   PubMed Web of Science ®Google Scholar
• CicenasS, VenceviciusV. Lung cancer in patients with tuberculosis. World J Surg Oncol. 2007;5:22. doi:10.1186/1477-7819-5-2217309797
   PubMedGoogle Scholar
• ShielsMS, AlbanesD, VirtamoJ, EngelsEA. Increased risk of lung cancer in men with tuberculosis in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 2011;20(4):672–678. doi:10.1158/1055-9965.EPI-10-116621335509
   PubMed Web of Science ®Google Scholar
• OhCM, RohYH, LimD, et al. Pulmonary tuberculosis is associated with elevated risk of lung cancer in Korea: the Nationwide Cohort Study. J Cancer. 2020;11(7):1899–1906. doi:10.7150/jca.3702232194800
   PubMed Web of Science ®Google Scholar
• EvmanS, BaysungurV, AlpayL, et al. Management and surgical outcomes of concurrent tuberculosis and lung cancer. Thorac Cardiovasc Surg. 2017;65(7):542–545. doi:10.1055/s-0036-158316727111500
   PubMed Web of Science ®Google Scholar
• ZhangJ, IwanagaK, ChoiKC, et al. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res. 2008;1(3):201–207. doi:10.1158/1940-6207.CAPR-08-0014
   PubMed Web of Science ®Google Scholar
• ChoiCM, KimMY, LeeJC, KimHJ. Advanced lung adenocarcinoma harboring a mutation of the epidermal growth factor receptor: CT findings after tyrosine kinase inhibitor therapy. Radiology. 2014;270(2):574–582. doi:10.1148/radiol.1312182424086072
   PubMed Web of Science ®Google Scholar
• MaemondoM, InoueA, KobayashiK, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380–2388. doi:10.1056/NEJMoa090953020573926
   PubMed Web of Science ®Google Scholar
• DeardenS, StevensJ, WuYL, BlowersD. Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013;24(9):2371–2376. doi:10.1093/annonc/mdt20523723294
   PubMed Web of Science ®Google Scholar
• RamalingamSS, VansteenkisteJ, PlanchardD, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50. doi:10.1056/NEJMoa191366231751012
   PubMed Web of Science ®Google Scholar
• HongS, GaoF, FuS, et al. Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-mutant advanced non-small cell lung cancer. JAMA Oncol. 2018;4(5):739–742. doi:10.1001/jamaoncol.2018.004929596544
   PubMed Web of Science ®Google Scholar
• CaoS, LiJ, LuJ, ZhongR, ZhongH. Mycobacterium tuberculosis antigens repress Th1 immune response suppression and promotes lung cancer metastasis through PD-1/PDl-1 signaling pathway. Cell Death Dis. 2019;10(2):44. doi:10.1038/s41419-018-1237-y30718463
   PubMed Web of Science ®Google Scholar